Fig. 4: Overall survival by baseline serum interferon gamma (IFNy). | Nature Communications

Fig. 4: Overall survival by baseline serum interferon gamma (IFNy).

From: Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

Fig. 4

Kaplan–Meier survival curves for patients with low baseline serum IFNy (blue) and high baseline serum IFNy (green) in Arm A (targeted therapy followed by immunotherapy), Arm B (immunotherapy followed by targeted therapy), and Arm C (a course of targeted therapy preceding immunotherapy and targeted therapy) of SECOMBIT. Dotted lines represent 95% confidence intervals. Source data are provided as a Source Data file.

Back to article page